\-\ Texto\\:\\ \ \(0\)\
\-\ slight\\ decreased\\ range\\ of\\ motion\\ when\\ compared\\ to\\ the\\ left\\ side\\.\ \(0\)\
\-\ a\\ trial\\ of\\ abduction\\ bracing\\ could\\ be\\ instituted\\ with\\ close\\ follow\\ up\\.\\ \\ treatment\\ of\\ pain\\ as\\ needed\\.\ \(0\)\
\-\ collapse\\ of\\ the\\ right\\ femoral\\ head\\ with\\ mixed\\ lucency\\ and\\ sclerosis\\ within\\.\\ \\ there\\ is\\ a\\ developing\\ coxa\\ cagna\\ breva\\ deformity\\ on\\ right\\ compared\\ to\\ the\\ normal\\ left\\ side\\.\ \(0\)\
\-\ legg\\-calve\\-perthes\ \(0\)\
\-\ avn\\ of\\ hip\\:\ \(0\)\
\-\ legg\\-calve\\-perthes\ \(0\)\
\-\ sickle\\ cell\\ disease\ \(41\)\
\-\ gaucher\\ disease\ \(1\)\
\-\ multiple\\ epiphyseal\\ dysplasia\ \(0\)\
\-\ cortico\\ steroid\\ use\ \(0\)\
\-\ 4\\ y\\/o\\ boy\\ with\\ chronic\\ right\\ hip\\ pain\\ with\\ which\\ is\\ progressively\\ worsening\\.\ \(1\)\
\-\ with\\ the\\ diagnosis\\ of\\ legg\\-calve\\-perthes\\,\\ approx\\.\\ 15\\%\\ can\\ be\\ bilateral\\.\\ \\ this\\ patient\\ will\\ then\\ need\\ follow\\-up\\ not\\ only\\ of\\ the\\ affected\\ side\\,\\ to\\ follow\\ its\\ progress\\ and\\ remodeling\\,\\ but\\ to\\ assess\\ the\\ opposite\\ side\\ for\\ any\\ evidence\\ of\\ involvement\\.\\ \\ this\\ patient\\ will\\ also\\ have\\ an\\ increased\\ risk\\ of\\ early\\ osteoarthritis\\ secondary\\ to\\ the\\ altered\\ mechanics\\ in\\ the\\ affected\\ hip\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ side\\:\\ 0\\.2416246122560765\ \(0\)\
\-\ hip\\:\\ 0\\.20150785788151027\ \(0\)\
\-\ of\\:\\ 0\\.15400490695154156\ \(0\)\
\-\ affected\\:\\ 0\\.14383491482390465\ \(0\)\
\-\ follow\\:\\ 0\\.14141355121253524\ \(0\)\
\-\ compared\\:\\ 0\\.1413810219795539\ \(0\)\
\-\ cagna\\:\\ 0\\.1398358846699131\ \(0\)\
\-\ breva\\:\\ 0\\.1398358846699131\ \(0\)\
\-\ the\\:\\ 0\\.1395798752733914\ \(0\)\
\-\ cortico\\:\\ 0\\.12579038736201614\ \(0\)\
\-\ mechanics\\:\\ 0\\.12063272317394881\ \(0\)\
\-\ bracing\\:\\ 0\\.1185858675740986\ \(0\)\
\-\ coxa\\:\\ 0\\.11516537881410888\ \(0\)\
\-\ will\\:\\ 0\\.11255767932125521\ \(0\)\
\-\ instituted\\:\\ 0\\.11237063600373111\ \(0\)\
\-\ to\\:\\ 0\\.10929936704022139\ \(0\)\
\-\ gaucher\\:\\ 0\\.10703156559028223\ \(0\)\
\-\ avn\\:\\ 0\\.10454037026620162\ \(0\)\
\-\ opposite\\:\\ 0\\.1030793941509912\ \(0\)\
\-\ approx\\:\\ 0\\.09994017286299614\ \(0\)\
\-\ abduction\\:\\ 0\\.09832513869583413\ \(0\)\
\-\ trial\\:\\ 0\\.0973358504782841\ \(0\)\
\-\ remodeling\\:\\ 0\\.0973358504782841\ \(0\)\
\-\ epiphyseal\\:\\ 0\\.09686416258062372\ \(0\)\
\-\ progress\\:\\ 0\\.08903389684309423\ \(0\)\
\-\ altered\\:\\ 0\\.08875769753022707\ \(0\)\
\-\ right\\:\\ 0\\.08697011340566191\ \(0\)\
\-\ up\\:\\ 0\\.08650672501908435\ \(0\)\
\-\ sickle\\:\\ 0\\.08647318372575152\ \(0\)\
\-\ with\\:\\ 0\\.08560940269263766\ \(0\)\
\-\ progressively\\:\\ 0\\.08555776864945182\ \(0\)\
\-\ steroid\\:\\ 0\\.08427964138793717\ \(0\)\
\-\ developing\\:\\ 0\\.08367844091537377\ \(0\)\
\-\ collapse\\:\\ 0\\.0820045635007442\ \(0\)\
\-\ assess\\:\\ 0\\.08081833064072788\ \(0\)\
\-\ need\\:\\ 0\\.08049561036000936\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.07986986441039741\ \(0\)\
\-\ close\\:\\ 0\\.07912197719986985\ \(0\)\
\-\ slight\\:\\ 0\\.07657249797613475\ \(0\)\
\-\ lucency\\:\\ 0\\.07526966700719193\ \(0\)\
\-\ disease\\:\\ 0\\.07340856301557058\ \(0\)\
\-\ mixed\\:\\ 0\\.07238059376286848\ \(0\)\
\-\ needed\\:\\ 0\\.0721936567248195\ \(0\)\
\-\ deformity\\:\\ 0\\.07146790474866763\ \(0\)\
\-\ be\\:\\ 0\\.07094197125728628\ \(0\)\
\-\ range\\:\\ 0\\.06785371425139922\ \(0\)\
\-\ motion\\:\\ 0\\.06778387974727973\ \(0\)\
\-\ dysplasia\\:\\ 0\\.06696977797529718\ \(0\)\
\-\ use\\:\\ 0\\.06690384820853486\ \(0\)\
\-\ worsening\\:\\ 0\\.0667728333328309\ \(0\)\
\-\ femoral\\:\\ 0\\.06498913693690196\ \(0\)\
\-\ its\\:\\ 0\\.06470153662154457\ \(0\)\
\-\ could\\:\\ 0\\.06360223796274411\ \(0\)\
\-\ involvement\\:\\ 0\\.0632872546782594\ \(0\)\
\-\ early\\:\\ 0\\.06302962429212267\ \(0\)\
\-\ pain\\:\\ 0\\.06257862911256531\ \(0\)\
\-\ risk\\:\\ 0\\.0624776330019222\ \(0\)\
\-\ sclerosis\\:\\ 0\\.06228173708159511\ \(0\)\
\-\ then\\:\\ 0\\.061897299449053755\ \(0\)\
\-\ this\\:\\ 0\\.06009204149201853\ \(0\)\
\-\ boy\\:\\ 0\\.0598148922743771\ \(0\)\
\-\ left\\:\\ 0\\.05965550539265149\ \(0\)\
\-\ 15\\:\\ 0\\.05908674575832479\ \(0\)\
\-\ patient\\:\\ 0\\.05687980234940549\ \(0\)\
\-\ any\\:\\ 0\\.05651084523545803\ \(0\)\
\-\ only\\:\\ 0\\.05462766463039289\ \(0\)\
\-\ decreased\\:\\ 0\\.054162243006069415\ \(0\)\
\-\ when\\:\\ 0\\.052818928725952195\ \(0\)\
\-\ head\\:\\ 0\\.052151243907110525\ \(0\)\
\-\ chronic\\:\\ 0\\.05190199212033052\ \(0\)\
\-\ secondary\\:\\ 0\\.05182800011596209\ \(0\)\
\-\ cell\\:\\ 0\\.05001981192577689\ \(0\)\
\-\ evidence\\:\\ 0\\.04963117751981263\ \(0\)\
\-\ is\\:\\ 0\\.04789217508994058\ \(0\)\
\-\ increased\\:\\ 0\\.04728349185269202\ \(0\)\
\-\ bilateral\\:\\ 0\\.04699357971904321\ \(0\)\
\-\ can\\:\\ 0\\.045885836687550786\ \(0\)\
\-\ diagnosis\\:\\ 0\\.04532836990268895\ \(0\)\
\-\ have\\:\\ 0\\.043681166474734856\ \(0\)\
\-\ but\\:\\ 0\\.04323930597747832\ \(0\)\
\-\ multiple\\:\\ 0\\.04276889541385822\ \(0\)\
\-\ treatment\\:\\ 0\\.04165239777626508\ \(0\)\
\-\ also\\:\\ 0\\.041129355011034575\ \(0\)\
\-\ within\\:\\ 0\\.04027225087281959\ \(0\)\
\-\ which\\:\\ 0\\.039759920138356775\ \(0\)\
\-\ and\\:\\ 0\\.036136885617418325\ \(0\)\
\-\ normal\\:\\ 0\\.03570123945607655\ \(0\)\
\-\ as\\:\\ 0\\.03512782385927219\ \(0\)\
\-\ there\\:\\ 0\\.03479217651952927\ \(0\)\
\-\ not\\:\\ 0\\.03451930334371038\ \(0\)\
\-\ an\\:\\ 0\\.03343683157389874\ \(0\)\
\-\ for\\:\\ 0\\.026502447684890698\ \(0\)\
\-\ on\\:\\ 0\\.02640843544821259\ \(0\)\
\-\ in\\:\\ 0\\.021752279156403237\ \(0\)\
